Abstracts tagged "Cardiovascular"

Abstract Number: 0900 • ACR Convergence 2022
Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, Jon Giles², George Reed³, Kevin Kane⁴, Jeffrey Curtis⁵ and Joel Kremer⁶, ¹CorEvitas, LLC, Waltham, MA, ²Columbia University, New York, NY, ³The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁴University of Massachusetts, Worcester, MA, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Cardiovascular (CV) risk in RA is increased due to interaction between traditional risk factors and systemic inflammation. The purpose of this analysis was to…
Abstract Number: 1216 • ACR Convergence 2022
Subclinical Vascular Disease Is More Prevalent in above-30 Adult Fibromyalgia: A Preliminary Report of a Hospital-based Cross-sectional Study from South India
Salil Ganu, C. B. Mithun and Jyothi Visalakshy, Amrita Institute of Medical Sciences, Kochi, India
Background/Purpose: Fibromyalgia is known to be associated with cardiovascular events and mortality. We aimed to compare the prevalence of subclinical atherosclerosis (SAT), a surrogate marker…
Abstract Number: 1532 • ACR Convergence 2022
The Primary Cardiomyopathy of Systemic Sclerosis on Cardiovascular Magnetic Resonance Imaging
sanya Chhikara¹, Adinan Kanda², mohamed Ismail², Fredrick Ogugua², Rejowana Rouf², khaled Ismail², Parag Bawaskar², Jerry Molitor² and Chetan Shenoy², ¹University of Minnesota, New York, NY, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Cardiac disease in systemic sclerosis (SSc) may be primary or secondary to coronary artery disease, pulmonary, or renal disease. The prevalence of the primary…
Abstract Number: 1815 • ACR Convergence 2022
Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Gary Ho¹, Michael Toprover², Daria Crittenden³, binita Shah⁴ and Michael Pillinger⁵, ¹New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ²Division of Rheumatology, New York University Grossman School of Medicine and Rheumatology Section, New York Harbor Health Care System, New York Campus of the U.S. Department of Veterans Affairs, New York, NY, ³CymaBay Therapeutics, New York University Grossman School of Medicine, Newark, CA, ⁴New York University Grossman School of Medicine, VA New York Harbor Health Care System, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Patients with gout are more likely than those without to have traditional risk factors for cardiovascular (CV) disease. Furthermore, the chronic, low-level inflammation experienced…
Abstract Number: 2215 • ACR Convergence 2022
Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis
Daniel Solomon¹, Jon Giles², Katherine Liao¹, Paul Ridker¹, Pamela Rist¹, Robert Glynn¹, Rachel Broderick³, Fengxin Lu¹, Meredith Murray¹, Kathleen Vanni¹, Leah Santacroce¹, Shady Abohashem⁴, Philip Robson⁵, Zahi Fayad⁶, Venkatesh Mani⁵, Ahmed Tawakol⁴ and Joan Bathon⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Columbia University, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Mount Sinai, New York, NY, ⁷Columbia University Medical Center, New York, NY
Background/Purpose: Recent large-scale randomized trials demonstrate that immunomodulators reduce the risk of cardiovascular (CV) events among the general population with atherosclerosis. However, it is uncertain…
Abstract Number: 0171 • ACR Convergence 2022
Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?
Matilde Bandeira¹, Eduardo Dourado¹, Ana Teresa Melo¹, Patricia Martins², Vanessa Fraga³, José Luís Ferraro⁴, André Saraiva⁵, Marlene Sousa⁶, Hugo Parente⁷, Catarina Soares⁸, Ana Margarida Correia⁹, Diogo Esperança Almeida⁹, Sara Paiva Dinis¹⁰, Ana Pinto¹¹, Filipe Pinheiro¹², Maria Rato¹², Tiago Beirão¹³, Beatriz Samões¹³, Bernardo Santos¹⁴, Carolina Mazeda¹⁵, Ana Teodósio Chícharo¹⁶, Margarida Faria¹⁷, Agna Neto¹⁷, Helena Lourenço¹⁸, Luísa Brites¹⁹, Marília Rodrigues¹⁹, Joana Silva-Dinis²⁰, João Madruga-Dias²¹, Filipe Araújo²², Nádia Martins²³, Maura Couto²³, Ana Valido²⁴, Maria José Santos²⁵, Sofia Barreira¹, João Eurico Fonseca¹ and Raquel Campanilho-Marques¹, ¹Serviço de Reumatologia, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa (CAML), Lisboa, Portugal; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, CAML, Lisboa, Portugal, ²Rheumatology department, Centro Hospitalar e Universitário de Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ³Serviço de Reumatologia, Hospital Beatriz Ângelo, Almada, Portugal, ⁴Serviço de Reumatologia, Hospital Beatriz Ângelo, Loures, Portugal, ⁵Rheumatology department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁶Serviço de Reumatologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, ⁷Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁸Rheumatology department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Viana do Castelo, Portugal, ⁹Serviço de Reumatologia, Hospital de Braga, Braga, Portugal, Braga, Portugal, ¹⁰Rheumatology department, Unidade Local de Saúde da Guarda - Hospital Sousa Martins, Guarda, Portugal, ¹¹Local Health Unit of Guarda, Barcelos, Portugal, ¹²Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ¹³Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, ¹⁴Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ¹⁵Centro Hospitalar Baixo Vouga, Ovar, Portugal, ¹⁶Serviço de Reumatologia, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ¹⁷Serviço de Reumatologia, Hospital Nélio Mendonça, Serviços de Saúde da Região Autónoma da Madeira, Funchal, Portugal, ¹⁸Serviço de Reumatologia, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ¹⁹Serviço de Reumatologia, Centro Hospitalar de Leiria, Leiria, Portugal, Leiria, Portugal, ²⁰Serviço de Reumatologia, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal, ²¹Rheumatology Service, Centro Hospitalar Médio Tejo, Tomar, Portugal, ²²Rheumatology and Osteoporosis Unit, Hospital de Sant´Ana, SCML, Lisboa, Portugal, ²³Rheumatology department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal, ²⁴Serviço de Reumatologia, Unidade Local de Saúde do Litoral Alentejano, Santiago do Cacém, Portugal, ²⁵Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare disorders that can affect the heart. It is unclear which patients are at higher risk.…
Abstract Number: 0477 • ACR Convergence 2022
Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?
Hubert De Boysson¹, Anael DUMONT², Samuel DESHAYES², Alexandre Nguyen² and Achille Aouba¹, ¹Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ²Caen University Hospital, Caen, France
Background/Purpose: We analyzed whether the use of beta-blockers in addition to conventional care in patients with Giant cell arteritis (GCA) and large vessel vasculitis (LVV)…
Abstract Number: 0903 • ACR Convergence 2022
Plasma Inflammatory Protein Biomarkers May Predict Cardiovascular Events in Early Rheumatoid Arthritis
Emil Rydell¹, Lennart Jacobsson² and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease (CVD). Systemic inflammation, driven by cytokines such as TNF, IL-6 and IL-17A,…
Abstract Number: 1240 • ACR Convergence 2022
A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy for the Diagnosis of Cardiac Sarcoidosis
Omar Abialmouna¹, Mohamad Kalot², Mohamad Hamade³, Ronak Bahuva², Ariba Hasmi², Aamir Ahmed², Zachary Brumberger², Jordan Troy², Ali Choaib⁴, Ronak Bharucha², Ross Moyer², Karin Provost², Brian Page² and Umesh Sharma², ¹University at Buffalo, North Tonawanda, NY, ²University at Buffalo, Buffalo, NY, ³University of Miami, Miami, FL, ⁴Lebanese American University, Beirut, Lebanon
Background/Purpose: Autopsy reports for patients with sarcoidosis have suggested that up to 25% have cardiac involvement, mostly undiagnosed. Given the limited diagnostic accuracy of endomyocardial…
Abstract Number: 1535 • ACR Convergence 2022
Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis
Jessica Fairley¹, Laura Ross², Alannah Quinlivan³, Dylan Hansen⁴, Elizabeth Paratz⁵, Wendy Stevens⁴, Peter M Kistler⁶, Andre La Gerche⁷ and Mandana Nikpour⁸, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ³St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Australia, ⁵The Baker Institute; St Vincent's Hospital Melbourne, Melbourne, Australia, ⁶The Baker Heart and Diabetes Institute; The University of Melbourne; Monash University, Melbourne, Australia, ⁷The Baker Heart and Diabetes Institute; The University of Melbourne, Melbourne, Australia, ⁸The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) Heart Involvement (SHI) is an under recognised complication of SSc and may manifest as arrhythmias or sudden cardiac death(SCD). The incidence of…
Abstract Number: 1816 • ACR Convergence 2022
Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
Ira Khanna, Venkatesh Mani, Renata Pyzik, Audrey Kaufman, Wei Wei Chi, Emilia Bagiella, Philip Robson and Yousaf Ali, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Gout is the most common inflammatory arthritis, caused by hyperuricemia and subsequent deposition of aggregated monosodium urate (MSU) crystals in both articular and extra-articular…
Abstract Number: 2217 • ACR Convergence 2022
Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity
Amir Razmjou¹, Jennifer Wang¹, Ani Shahbazian¹, Jeffrey Curtis², Dimitrios Pappas³, Joel Kremer⁴ and Christina Charles-Schoeman⁵, ¹UCLA Medical Center, Los Angeles, CA, ²University of Alabama at Birmingham, Hoover, AL, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation, Delray Beach, FL, ⁵Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA
Background/Purpose: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme with paraoxonase, lactonase, and arylesterase activities (1). PON1 is integral to the anti-inflammatory, anti-atherogenic functions of…
Abstract Number: 0244 • ACR Convergence 2022
Identification of Novel Response Predictors via Cardiovascular Biomarker Proteomic Analysis of Serum Samples from Patients with Early, Seropositive RA Treated with Abatacept or Adalimumab
Yicong Li¹, Chun Wu², Michael Maldonado², Peter Schafer², S. Louis Bridges, Jr.³, William Rigby⁴, Vivian Bykerk³, Jane Buckner⁵ and Jinqi Liu², ¹Parexel International, Durham, NC, ²Bristol Myers Squibb, Princeton, NJ, ³Hospital for Special Surgery, New York, NY, ⁴Dartmouth Hitchcock Medical Center, Lebanon, PA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Effective RA therapies should not only improve joint signs and symptoms, but also mitigate additional disease-related consequences, such as the increased risk of cardiovascular…
Abstract Number: 0539 • ACR Convergence 2022
Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use
Anna Broder¹, Wenzhu B. Mowrey², Kazuki Yoshida³ and Karen Costenbader³, ¹Hackensack University Medical Center, Hackensack, NJ, ²Albert Einstein College of Medicine, Bronx, NY, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…
Abstract Number: 0908 • ACR Convergence 2022
The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis
Arkady Manning-Bennett¹, Ashley Hopkins², Michael Sorich², Susanna Proudman³, David Foster¹, Ahmad Abuhelwa² and Michael Wiese¹, ¹University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that is characterised by inflammation in the synovium of diarthrodial joints and low-level inflammation in multiple…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].